The aim of the current study is to determine, correlate and compare the plasma lipoprotein-associated phospholipase A2 (Lp-PLA2), vitronectin (Vn), Plasminogen activator inhibitor-1 (PAI-1) activity and tissue plasminogen activator (t-PA) levels in early-onset preeclampsia, late-onset preeclampsia and in control pregnant women.
A total of 79 individuals, 30 early-onsets, and 22 late-onset preeclamptic and 27 control pregnant women were included into the scope of this study. Enzyme-linked immunosorbent assay procedure was used to determine the serum Lp-PLA2 and plasma Vn, t-PA antigen and PAI-1 activity levels. Serum C-reactive protein (CRP) levels were measured immunoturbidimetrically in routine clinical chemistry analyser.
In patients with preeclampsia, Lp-PLA2, PAI-1, t-PA, CRP and blood pressures levels were increased (p = 0.000) and correlated with each other. Vn levels were decreased (p = 0.016) but not correlated with other parameters in preeclamptic patients.
We are of the opinion that increased Lp-PLA2 levels may partially contribute to endothelial dysfunction by the progression of inflammation. In addition, increased complex formation with Vn is likely to bring about the increase of PAI-1 activity in patients with preeclampsia. Moreover, increased t-PA and decreased Vn levels may also be the consequences of compensatory mechanisms against disease progression.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
ACOG Committee on Obstetric Practice (2002) ACOG practice bulletin. Diagnosis and management of preeclampsi and eclampsia. Number 33, January 2002. American College of Obsteticians and Gynecologists. Int J Gynaecol Obstet 77(1):67–75
Weiss G, Goldsmith LT, Taylor RN, Bellet D, Taylor HS (2009) Inflammation in reproductive disorders. Reprod Sci 16(2):216–229
Fan P, Liu XH, He GL, Zhang S, Zhang JX, Bai H (2012) Maternal and fetal plasma platelet-activating factor acetylhydrolase activity and distribution in pre-eclampsia. Pediatr Res 72(4):426–431
Ramma W, Ahmed A (2011) Is inflammation the cause of pre-eclampsia? Biochem Soc Trans 39(6):1619–1627
Dusse LM, Rios DR, Pinheiro MB, Cooper AJ, Lwaleed BA (2011) Pre-eclampsia: relationship between coagulation, fibrinolysis and inflammation. Clin Chim Acta 412(1–2):17–21
Boij R, Svensson J, Nilsson-Ekdahl K, Sandholm K, Lindahl TL, Palonek E, Garle M, Berg G, Ernerudh J, Jenmalm M, Matthiesen L (2012) Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol 68(3):258–270
Abbate R, Cioni G, Ricci I, Miranda M, Gori AM (2012) Thrombosis and acute coronary syndrome. Thromb Res 129(3):235–240
Yang EH, McConnell JP, Lennon RJ, Barsness GW, Pumper G, Hartman SJ, Rihal CS, Lerman LO, Lerman A (2006) Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 26(1):106–111
Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A (2007) Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 115(21):2715–2721
Garg PK, McClelland RL, Jenny NS, Criqui M, Liu K, Polak JF, Jorgensen NW, Cushman M (2011) Association of lipoprotein-associated phospholipase A (2) and endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA). Vasc Med 16(4):247–252
Aso Y (2007) Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 12:2957–2966
Wikström AK, Nash P, Eriksson UJ, Olovsson MH (2009) Evidence of increased oxidative stress and a change in the plasminogen activator inhibitor (PAI)-1 to PAI-2 ratio in early-onset but not late-onset preeclampsia. Am J Obstet Gynecol 201(6):597.e1–597.e8
Ekmekçi OB, Ekmekçi H (2006) Vitronectin in atherosclerotic disease. Clin Chim Acta 368(1–2):77–83
ACOG Committee on Obstetric Practice (2002) ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 99(1):159–167
Greer IA, Dawes J, Johnston TA, Calder AA (1991) Neutrophil activation is confined to the maternal circulation in pregnancy-induced hypertension. Obstet Gynecol 78(1):28–32
Lynch AM, Murphy JR, Gibbs RS, Levine RJ, Giclas PC, Salmon JE, Holers VM (2010) The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 117(4):456–462
Szarka A, Rigó J Jr, Lázár L, Beko G, Molvarec A (2010) Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 11:59
Renckens R, Roelofs JJ, de Waard V, Florquin S, Lijnen HR, Carmeliet P, van der Poll T (2005) The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost 3(5):1018–1025
Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS, Mallet AI, Poston L (2002) A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 187(1):127–136
Tabak O, Gelisgen R, Uzun H, Kalender B, Balci H, Curgunlu A, Simsek G, Karter Y (2009) Hypertension and hemostatic/fibrinolytic balance disorders. Clin Invest Med 32(6):E285–E292
Tanjung MT, Siddik HD, Hariman H, Koh SC (2005) Coagulation and fibrinolysis in preeclampsia and neonates. Clin Appl Thromb Hemost 11(4):467–473
Shen J, Ma X, Yi F, Rasul A, Cui M, Ma T (2013) Increased expression levels of vitronectin in the maternal fetal interface of placenta in early-onset severe preeclampsia. Mol Med Rep 7(1):53–58
Asch E, Podack E (1990) Vitronectin binds to activated human platelets and plays a role in platelet aggregation. J Clin Invest 85(5):1372–1378
Mohri H, Ohkubo T (1991) How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation. Am J Clin Pathol 96(5):605–609
Reheman A, Gross P, Yang H, Chen P, Allen D, Leytin V, Freedman J, Ni H (2005) Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost 3(5):875–883
This study was supported by Istanbul University, Scientific Research Projects Unit (Project Number: BYP-20082).
Conflict of interest
About this article
Cite this article
Balcı Ekmekçi, Ö., Ekmekçi, H., Güngör, Z. et al. Evaluation of Lp-PLA2 mass, vitronectin and PAI-1 activity levels in patients with preeclampsia. Arch Gynecol Obstet 292, 53–58 (2015). https://doi.org/10.1007/s00404-014-3601-1
- Endothelial dysfunction